Dimensional Fund Advisors LP Sells 22,886 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Dimensional Fund Advisors LP trimmed its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Rating) by 3.0% during the third quarter, HoldingsChannel.com reports. The firm owned 730,882 shares of the biopharmaceutical company’s stock after selling 22,886 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Intra-Cellular Therapies were worth $34,005,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Illinois Municipal Retirement Fund bought a new stake in shares of Intra-Cellular Therapies in the second quarter valued at about $576,000. Assenagon Asset Management S.A. lifted its holdings in shares of Intra-Cellular Therapies by 21.0% in the third quarter. Assenagon Asset Management S.A. now owns 47,422 shares of the biopharmaceutical company’s stock valued at $2,207,000 after purchasing an additional 8,232 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Intra-Cellular Therapies in the third quarter valued at about $41,000. Mackenzie Financial Corp increased its position in shares of Intra-Cellular Therapies by 1,153.7% in the second quarter. Mackenzie Financial Corp now owns 56,930 shares of the biopharmaceutical company’s stock valued at $3,250,000 after acquiring an additional 52,389 shares during the last quarter. Finally, US Bancorp DE increased its position in shares of Intra-Cellular Therapies by 93.8% in the second quarter. US Bancorp DE now owns 496 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 240 shares during the last quarter. 86.95% of the stock is currently owned by institutional investors.

Intra-Cellular Therapies Trading Down 5.7 %

Intra-Cellular Therapies stock opened at $46.52 on Friday. Intra-Cellular Therapies, Inc. has a 12 month low of $42.42 and a 12 month high of $66.00. The stock’s 50 day moving average is $49.12 and its 200-day moving average is $49.51. The company has a market capitalization of $4.41 billion, a price-to-earnings ratio of -14.01 and a beta of 1.13.

Intra-Cellular Therapies (NASDAQ:ITCI – Get Rating) last posted its earnings results on Wednesday, March 1st. The biopharmaceutical company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.17. Intra-Cellular Therapies had a negative return on equity of 45.52% and a negative net margin of 158.39%. The company had revenue of $87.87 million for the quarter, compared to the consensus estimate of $86.97 million. During the same quarter in the prior year, the business earned ($1.05) earnings per share. The firm’s revenue for the quarter was up 242.3% on a year-over-year basis. As a group, equities research analysts predict that Intra-Cellular Therapies, Inc. will post -2.86 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on ITCI shares. Royal Bank of Canada lowered their target price on Intra-Cellular Therapies from $75.00 to $71.00 and set an “outperform” rating on the stock in a research report on Thursday. Needham & Company LLC reaffirmed a “buy” rating and issued a $70.00 target price on shares of Intra-Cellular Therapies in a research report on Wednesday. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $83.00 target price on shares of Intra-Cellular Therapies in a research report on Wednesday, February 1st. Canaccord Genuity Group lifted their target price on Intra-Cellular Therapies from $90.00 to $93.00 in a research report on Friday, November 4th. Finally, StockNews.com raised Intra-Cellular Therapies from a “sell” rating to a “hold” rating in a research report on Friday, November 4th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $71.33.

Insider Activity

In other news, CEO Sharon Mates sold 33,083 shares of the company’s stock in a transaction that occurred on Tuesday, December 13th. The stock was sold at an average price of $55.00, for a total value of $1,819,565.00. Following the transaction, the chief executive officer now owns 1,100,309 shares of the company’s stock, valued at $60,516,995. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Sharon Mates sold 33,083 shares of the company’s stock in a transaction that occurred on Tuesday, December 13th. The stock was sold at an average price of $55.00, for a total value of $1,819,565.00. Following the transaction, the chief executive officer now owns 1,100,309 shares of the company’s stock, valued at $60,516,995. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Joel S. Marcus sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, December 19th. The shares were sold at an average price of $50.82, for a total value of $254,100.00. Following the completion of the transaction, the director now directly owns 29,233 shares in the company, valued at approximately $1,485,621.06. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 184,591 shares of company stock valued at $9,106,853. 3.70% of the stock is owned by insiders.

Intra-Cellular Therapies Profile

(Get Rating)

Intra-Cellular Therapies, Inc operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS.